Article Sidebar
Published:
Sep 21, 2022DOI:
10.4314/tjpr.v21i8.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
PLOD1 contributes to proliferation and glycolysis in hepatocellular carcinoma by regulating E2F1
Abstract
Purpose: To evaluate the effect of procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1 (PLOD1) in hepatocellular carcinoma (HCC).
Methods: HCC cells were subjected to loss of function assays via transfection with siRNA targeting PLOD1. Colony formation and cell counting kit 8 (CCK8) were used to determine cell proliferation. Cell cycle was evaluated by flow cytometry while extracellular acidification rate (ECAR) levels, glucose consumption, and lactate production were determined to investigate aerobic glycolysis.
Results: PLOD1 was significantly up-regulated in HCC tissues and cells compared to normal tissues and cells (p < 0.001). Silencing of PLOD1 significantly repressed cell proliferation (p < 0.001) and induced cell cycle arrest in HCC at the G1 phase. ECAR levels, glucose consumption, and lactate production in HCC were reduced by knockdown of PLOD1. Loss of PLOD1 down-regulated the expression of E2F1, while over-expression of E2F1 attenuated PLOD1 knockdown-induced decreases in cell viability, glucose consumption, and lactate production in HCC.
Conclusion: Knockdown of PLOD1 inhibits cell proliferation and aerobic glycolysis in HCC via down-regulation of E2F1. Thus, PLOD1 may help in developing an effective strategy for the management of liver cancer.
